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ABSTRACT 
In this work, a modified version of the 44 amino acid human growth hormone-
releasing hormone (hGHRH(1-44)) containing an N-terminal proline extension, a 
valine residue in position 14, and a C-terminus amidation (sequence: 
PYADAIFTNSYRKVVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2) has 
been identified in a confiscated product by liquid chromatography-high resolution 
mass spectrometry (LC-HRMS). Investigation of the product suggests also an 
incomplete C-term amidation. 
Similarly to other hGHRH analogues, available in black markets, this peptide can 
potentially be used as performance-enhancing drug due to its growth hormone 
releasing activity and therefore it should be considered as a prohibited substance in 
sport. Additionally, the presence of partially amidated molecule reveals the poor 
pharmaceutical quality of the preparation, an aspect which represents a big concern 
for public health as well. 
  
INTRODUCTION 
The use of peptide-based doping agents has become increasingly popular during the 
last years [1]. A relevant phenomenon for this class of substances is represented by 
unapproved peptide formulations [2-6]. According to the Prohibited List of substances 
and methods of the World Anti-Doping Agency (WADA) [7], any pharmacological 
substance without current approval by any governmental regulatory health authority 
for human therapeutic use, is prohibited. 
Unapproved drugs are generally not accessible through legal channels of distributions, 
but several cases have already demonstrated how they can find their way into black 
markets [2-6,8,9]. This phenomenon represents a big concern for public health, since 
these preparations are often prepared with no respect for good manufacturing practice, 
with lack or even total absence of information on composition. Moreover, these 
peptides do not usually undergo a complete toxicological evaluation (e.g.: TB-500) 
[6], and therefore the risks associated with the intake are unpredictable. 
In sport drug testing, identification of new peptides with performing-enhancing 
properties is a first important step towards the development of effective detection 
methods for monitoring their misuse in sports [10,11]. In this context, collaboration 
between controlling authorities and laboratories has a crucial role in the battles 
against illegal trade of peptide hormones. 
Recently, an unknown preparation, consisting of an unlabeled vial containing 
lyophilized powder (Figure 1), was confiscated by Belgian Customs authorities and 
then delivered to our laboratory for identification. The product was characterized by 




Acetonitrile and water (LC grade) were purchased from BioSolve (Lexington MA, 
USA). Glacial acetic acid was purchased from Merck (Darmstadt, Germany). Formic 
acid was purchased from Fischer Scientific (Loughborough, UK). Sequencing Grade 
Modified Trypsin was purchased from Promega (Madison, WI, USA). Ammonium 
bicarbonate was purchased by Sigma-Aldrich (St. Louis, MI, USA) 
Stock solution of the unknown product was prepared by dissolving the content of the 
vial in water (1 mg/mL). For direct injection, sample was diluted 1:10 with 2% acetic 
acid. 
Trypsin digestion 
100 µL stock solution was evaporated to dryness (40 °C) and reconstituted in 200 µL 
trypsin solution (10 µg/mL in 25mM ammonium bicarbonate buffer, pH 8). Sample 
was incubated under gentle stirring for 24 hours at 37 °C. Trypsin digestion was 
stopped with 2% acetic acid (50 µL), and samples were then injected in the LC-MS 
system. 
Liquid chromatography 
The UHPLC system consisted of an Accela LC (Thermo Scientific, Bremen, 
Germany) equipped with degasser, Accela 1250 pump, autosampler thermostated at 
10°C and a heated column compartment. LC separation was performed using a 
Zorbax SB-C8, 2.1 x 50 mm and 1.8 µm particle size from Agilent Technologies 
(Böblingen, Germany) thermostated at 25°C. The mobile phases were 0.2% formic 
acid in water (A) and 0.2% formic in acetonitrile (B). The gradient program was as 
follows: 100% A for 5 min, then decreased linearly to 0% in 8.0 min, and held at 0% 
for 2 min followed by an increase to the initial concentration of 100% A in 0.1 min. 
Equilibrium time was 5 min resulting in a total run time of 20 min. The flow rate was 
set constant at 250 µL/min and the injection volume was 10 µL. 
High-resolution mass spectrometry 
HRMS characterization was performed using a Q-Exactive benchtop, Orbitrap™-
based mass spectrometer (Thermo Scientific, Bremen, Germany) operated in positive-
negative polarity switching mode and equipped with a heated electrospray ion source 
(HESI). Nitrogen sheath gas flow rate and auxiliary gas were set at 60 and 30 
(arbitrary units), respectively. The capillary temperature was 350°C, the spray voltage 
3 kV or -3 kV and the capillary voltage 30 V or -25 V, respectively in positive or 
negative ion modes. The instrument operated from m/z 300 to 3 000 at 70 000 
resolving power in full scan (FSMS). The automatic gain control (AGC) was set to 
10e6. The data acquisition rate was 2 Hz. 
FSMS experiments were followed by targeted MS/MS (tMSMS) experiments at a 
normalized collision energy (NCE) set at 30% for peptide sequencing. For tMSMS 
experiments, the instrument operated from m/z 100 to 1 500 at 17 500 resolving 
power and AGC set to 10e6. Isolation window of the quadrupole was set to 3.0 m/z. 
The Orbitrap™ performances in both positive and negative ionization modes were 
evaluated daily and when it failed, external calibration was performed with Exactive 
Calibration Kit solutions (Sigma-Aldrich, and ABCR GmbH & Co. KG, Karlsruhe, 
Germany). A mass extraction window of 5 ppm was used. 
Data analysis 
ProMass software from Thermo Fisher (Bremen, Germany) was used for spectral 
deconvolution. Protein Prospector v 5.10.19 was used to predict both trypsin digestion 
products and fragmentation of peptides for de novo sequencing [12]. 
RESULTS 
Identification of  [Pro1, Val14]-hGHRH 
HRMS is an ideal tool for identification of peptidic compounds due to the possibility 
to determine the amino acid sequence of a peptide based upon its MS/MS spectrum. 
Preliminary analysis constisted of direct injection for FSMS analysis. Figure 2 shows 
full scan FSMS spectrum of the unknown compound, which presents a cluster of 
multicharged ions in positive mode (typical for peptides) in the m/z range 500-2000, 
whereby the six-fold charged ion at m/z 872.9687 is the most abundant. Mass 
spectrum deconvolution yielded a monoisotopic mass  5233. 7555 Da. 
In order to obtain better peptide sequencing, the peptide was incubated with the 
proteolytic enzyme trypsin. Tryptic digestion allowed for the formation of smaller 
subunits of the peptide (MW < 2000 Da) which could be easily sequenced for the 
identification of the intact peptide. Tryptic product peptides that were identified are 
all summarized on Table 1. As shown in Figure 3 for six representative peptides, de 
novo sequencing from MS/MS spectra of tryptic products generated by enzymatic 
digestion of the native peptide provided identification of the unknown substance as a 
46-aa modified version of human GHRH(1-44, corresponding to the sequence 
PYADAIFTNSYRKVVLGQLSARKLLQDIMSRQQGESNQERGARARL and to an 
exact monoisotopic mass of 5233,7637 Da, confirming the value obtained from 
spectral deconvolution of the native peptide. The peptide has a proline residue at the 
N–terminus (Figure 3a and 3b), a valine residue in position 14 (Figure 3b and 3c) and 
a C-term amidation which are not present in hGHRH and it will be further referred as 
[Pro1, Val14]-hGHRH. 
The valine in position 14 was the most surprising finding, since it was inserted as an 
additional amino acid and not, as expectable, in substitution of an amino acid (perhaps 
arginine or lysine, sensible to enzymatic degradation). On the other hand, N-terminal 
proline extension and C-terminal amidation have been described for GHRH analogues 
[13,14] 
Cleavage sites for [Pro1, Val14]-hGHRH were the carboxyl side of Arg12,22,31,39,43, 
and Lys13,23, which are typical cleavage sites for trypsin. Digestion products with 
missing cleavages were also detected (due to incomplete digestion); however, these 
peptides provided further confirmation of the sequence. 
C-terminus: an incomplete amidation? 
Analysis of the tryptic products, particularly of the product aa 44-46, revealed the 
presence of both free and amidated C-terminus. As shown in Figure 4, beside the 
ARL-OH pseudomolecular ion (m/z=359.2394) (Figure 5a), the ion 358.2554 (Δm/z= 
-0.9840) (Figure 5b) corresponding to the amidated peptide ARL-NH2 (theoretical 
m/z=358.2561, Δppm= -1.9) was detected. This result was confirmed by the detection 
of the two (y2-NH3)
+
 ions at m/z= 270.1922 (Δppm= -1.1) (Figure 4c) m/z=271.1758 
Δppm= -2.5) (Figure 4d). The ratio between the area of the peaks indicates that the 
free peptide is significantly more abundant than the amidated. Unfortunately, no 
appropriate reference standards were available to provide a more precise 
determination. 
As trypsin does not have deamidating activity, the free form could not be generated 
during the digestion. Traces of the amidated form (monoisotopic mass= 5232.7560) 
were also detected in the native peptide (Figure 4e and 4f). 
Amidation, a common strategy to improve the pharmacokinetics properties of a 
peptidic drug, is generally performed in the last stages of the synthesis. Moreover, 
amidation is present in other GHRH analogues [4]. This finding suggests an 
incomplete amidation of the peptide during the manufacturing process. This is a clear 
example of the lack of quality controls typically associated to the production of black 
market peptides. 
Misuse and detection of [Pro1, Val14]-hGHRH 
The human growth hormone-releasing hormone (GHRH) is a 44 amino acid 
hypothalamic peptide (sequence: 
(YADAIFNTSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL) that 
stimulates GH production and release [14]. GHRH analogues are considered as 
prohibited substances according to section S2 of WADA List (peptide hormones, 
growth factors and related substances) [7]. To the best of our knowledge, [Pro1, 
Val14]-hGHRH-NH2 has not been approved for any clinical application. 
There is reason to believe that [Pro1, Val14]-hGHRH might be marketed as 
performance-enhancing drug. Indeed, similar to other several other analogues of 
GHRH(1-44) and GHRH(1-29) (tesamorelin, sermorelin, CJC-1293 and CJC-1295) 
[4], [Pro1,Val14]-hGHRH appears to find its way to black market and is classified by 
the marketers as a performance-enhancing drug. GHRH analogues appear to be 
attractive especially to some communities such as bodybuilding and fitness. 
Obviously, no pharmacokinetics data are available for [Pro1, Val14]-hGHRH, but 
very low urinary and plasmatic concentrations (sub ng/mL) and short half-life can be 
expected. However, due to its similarity to other GHRH analogues, currently existing 
methods based on immunoaffinity purification followed by LC-MS detection should 
theoretically be able to monitor its abuse [10]. 
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FIGURE AND TABLE CAPTION 
Figure 1 
The product confiscated by Belgian Customs. 
Figure 2 
Full scan spectrum of the unknown peptide. 
Figure 3 
E MS/MS spectra for six representative [Pro1, Val14]-hGHRH-NH2 tryptic 
peptides.(b-f). The C-terminus peptide ARL was detected mainly in the free form (see 
Figure 5).  
 Figure 4 




 ions from 
tMSMS of tryptic product aa 44-46 ARL-OH (precursor ion at m/z= 359.2401) (a,c) 
reveal the presence, in a minor amount, of 44-46 ARL-NH2 (b,d), most likely due to 
an low yield of the amidation during the synthesis of the peptide. Traces of the 
amidated peptides were also detected in the full scan spectrum of the native peptide 
(e,f). 
Table 1 
List of tryptic peptides detected after digestion,including those with missing cleavages. 
